Novartis, which already has experience with RNA interference therapies, is now turning to this modality as a potential way to treat Parkinson’s disease. The pharmaceutical giant is licensing rights to an Arrowhead Pharmaceuticals RNAi therapy designed to inhibit production of alpha synuclein, a protein associated with Parkinson’s progression.
The post Novartis Tries Again in Parkinson’s, Putting Up $200M for Arrowhead’s RNAi Therapy appeared first on MedCity News.
